Published in Gene Therapy Weekly, October 19th, 2000
The studies, which the company believes will form the basis of an Investigative New Drug filing and commencement of a Phase Ib/II cancer study around year end, were part of data presented at the seventh annual CaP CURE prostate cancer scientific retreat held in September 2000.
Patrick Iversen, PhD, AVI, presented data on AVI's clinical development of Oncomyc-NG, a NeuGene antisense therapy that has completed preclinical studies and Phase I clinical trials. The compound targets the oncogene...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.